cobas® Liat® System
Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.
Fast trusted SARS-CoV-2 PCR results, to enable informed care decisions
SARS-CoV-2 may be difficult for clinicians to identify on symptoms alone. Many patients may be asymptomatic and if left undiagnosed, it may result in health complications or community spread.
With nearly 3.6 million deaths and nearly 171 million cases1 of COVID-19 reported so far worldwide, effective tools are needed to deliver rapid results to identify symptomatic and asymptomatic individuals.
cobas® SARS-CoV-2 is the first real-time polymerase chain reaction (PCR) test that provides targeted identification within 20 minutes for both asymptomatic and symptomatic persons, enabling informed decisions at the point of care.
Relying on the rapid and accurate cobas® SARS-CoV-2 performance, healthcare providers now have the urgent answers they need to rule-in or rule-out SARS-CoV-2.
Related Information
* cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System, Package Insert V01, Pleasanton, CA; Roche Molecular Systems, Inc., 2021.
** Compared to FDA EUA SARS-CoV-2 RT-PCR assays; IFU data.
CI=confidence intervals. LOD=limit of detection. TCID=tissue culture infective dose.
Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.
References
1. http://COVID19.who.int, Last accessed 3 Jun 21
Instrument
cobas® Liat® Analyser
Target
SARS-CoV-2
Sample type
Nasopharyngeal swab, nasal swab
Collection media
Universal Transport Media (UTM), 0.85 & 0.9% saline
Sample extraction
Fully automated and integrated
Technology
Real-time PCR
Control
Internal sample processing control, positive and negative controls
Time to result
~20 minutes
Reagents
Ready-to-use, pre-packed tube format
Kit Storage
2-8°C
Registration
Emergency Use Authorization (EUA); CE-IVD